SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is experiencing a sharp sell-off after reporting mixed Q4 earnings, where a revenue miss and conservative forward guidance overshadowed its profitability. The community is actively debating whether the market's strong negative reaction is an overdone response to broader fintech sector and macro credit concerns, or if it reflects justified apprehension regarding the company's cautious outlook.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group (CRDO) is surging after pre-announcing preliminary Q3 revenue significantly above prior guidance and consensus, coupled with a robust outlook for sequential growth into fiscal year 2027. The community is vigorously discussing this strong performance, highlighting its crucial role in the ongoing AI data center buildout and the massive capital expenditure increases from hyperscalers, expecting continued upward momentum.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

The FDA's issuance of a Complete Response Letter (CRL) for Regenxbio's RGX-121 gene therapy for Hunter syndrome is driving intense conversation, with the community expressing significant concerns about the trial design, financial implications, and potential dilution amidst broader scrutiny of gene therapy development.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl (KD) is in focus following the abrupt departure of its CFO and general counsel amidst an accounting review and delayed regulatory filings, triggering a severe sell-off. The community is debating whether the IT infrastructure provider's over 50% stock drop is an extreme overreaction and a buying opportunity, or a justified response to serious governance concerns.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

FISV is trending intensely ahead of its earnings, with the community sharply divided between those anticipating a strong rebound fueled by perceived undervaluation, recent institutional accumulation, and new leadership's strategic moves, and those fearing another significant drop due to past disappointments, heavy put option activity, and ongoing fintech sector concerns.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending following its robust Q4 earnings beat, though a mixed Q1 outlook is fueling debate among investors between short-term caution and long-term optimism regarding its pivotal role in advanced AI and data center packaging, bolstered by strategic investments and CHIPS Act funding.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Satellos Bioscience (MSLE) is generating significant buzz following its Nasdaq listing, a recent financing round, and a reverse stock split, sparking an active community debate on the revolutionary potential of its SAT-3247 drug for Duchenne muscular dystrophy against concerns regarding dilution and the early stage of its clinical development.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

CRO is trending following news of Trump Media's ($DJT) partnership with crypto.com/us for digital token distribution on the Cronos chain, with discussions also highlighting its potential inclusion and significant weighting in a proposed Crypto ETF. This development is driving considerable community debate, with some anticipating substantial growth while others express skepticism about the coin's future trajectory.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola is heavily discussed ahead of its imminent earnings report, as investors debate whether its traditional safe-haven status and dividend consistency justify its current valuation, with some community members noting recent price action and potential overextension.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is trending due to recent exchange listings and its expansion to the Solana blockchain, significantly increasing its accessibility and multi-chain utility. The community is actively discussing its AI agent-powered utility on the Base ecosystem, with many anticipating a significant price appreciation while others warn of potential volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Context Therapeutics (NASDAQ:CNTX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered Context Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday...

Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight research firms that are presently covering the firm...

Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen

Wall Street Zen raised Context Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...

Context Therapeutics (NASDAQ:CNTX) Coverage Initiated by Analysts at Jones Trading

Jones Trading initiated coverage on Context Therapeutics in a research report on Monday. They issued a "buy" rating and a $7.00 price objective for the company...

Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Recommendation of "Moderate Buy" by Brokerages

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine brokerages that are covering the stock, Marketbeat.com reports. One...

Context Therapeutics (NASDAQ:CNTX) Upgraded to "Sell" at Wall Street Zen

Wall Street Zen upgraded Context Therapeutics to a "sell" rating in a report on Saturday...

Context Therapeutics (NASDAQ:CNTX) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Context Therapeutics in a research report on Thursday...

Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results

Context Therapeutics (NASDAQ:CNTX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts...

Shares of Context Therapeutics Inc. rose over&nbsp;7% in Wednesday's pre-market trading after JMP Securities initiated coverage with an 'Outperform' rating and a price target of $4.&nbsp;The brokerage's target implies a near quadrupling from the stock's previous close and has fueled bullish sentiment among retail investors.In its research note, JMP highlighted Context's focus on developing next-generation T-cell-engaged bispecific antibody therapies for solid tumors.&nbsp;The micro-cap biotech is building a portfolio of in-licensed clinical-stage TCE bispecific antibodies, which the analyst described as "innovative."&nbsp;JMP also praised the management team's business development acumen in assembling a pipeline that it believes is “worth more than the sum of its parts.”Retail chatter on Stocktwits mirrored the analyst's enthusiasm, with one user predicting a move to $6 and another noting the stock could "come back in a hurry" after a period of limited news flow.<stembedurl>https://stocktwits.com/Leonkika/message/599089608</stembedurl><stembedurl>https://stocktwits.com/claybridge/message/598957638</stembedurl>Context Therapeutics' lead program, CTIM-76, is poised to enter clinical trials soon.&nbsp;According to D. Boral Capital, which issued a ‘Buy’ rating and a $9 price target in November, CTIM-76 targets Claudin 6, a tumor marker broadly expressed in solid tumors like gynecologic and testicular cancers but largely absent in healthy adult tissues.&nbsp;This specificity makes it a promising therapeutic target, the brokerage said.Context’s stock has lost over 8% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Context Therapeutics Stock Jumps Pre-Market On Analyst's Near 4x Upside View: Retail Pins High Hopes Too

The micro-cap biotech is building a portfolio of in-licensed clinical-stage TCE bispecific antibodies, which JMP described as "innovative”

Equity

The micro-cap biotech is building a portfolio of in-licensed clinical-stage TCE bispecific antibodies, which JMP described as "innovative”


Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

Context Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

CNTX
Context Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CNTX News

CNTXContext Therapeutics Inc